Marginally failed study for Europe [Study As­sess­ment]

posted by balakotu – India, 2018-04-24 07:30 (1576 d 10:35 ago) – Posting: # 18726
Views: 3,640

I have conducted a full replicate BE study for one of the highly variable product for Europe regulatory.
Based on the reference product variability, relaxed 90% Confidence Intervals is 75.18 to 133.01 for Cmax.
Study marginally failed with 90% upper CI data of 133.18
Is there any way to justify Europe regulatory authority(ies) to accept this study data? (DCP submission)


Edit: Category changed; see also this post #1 and #4. [Helmut]

Complete thread:

UA Flag
 Admin contact
22,305 posts in 4,668 threads, 1,587 registered users;
online 16 (1 registered, 15 guests [including 9 identified bots]).
Forum time: Wednesday 18:05 CEST (Europe/Vienna)

There is no point in being precise when you don’t know
what you’re talking about.    attributed to John Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz